Structural modifications, such as altering the prenyl side chains, hydroxyl positions, and phenolic substitutions, can enhance HAT selectivity, bioavailability, and tumor targeting, offering a rational path toward next-generation epigenetic therapeutics. This evidence concerns the gene TMPRSS11D and neoplasm.